FDA’s own sentence is the answer: “There are currently no FDA-approved exosome products.” That language has been on the agency’s public safety notification since December 6, 2019, and it appears again on FDA’s consumer alert on regenerative medicine products, listed as current as of April 9, 2024. No approved exosome product exists for any indication in the United States.
The biology is genuinely interesting, and Empire teaches it. The problem is that the market is ahead of the approvals — the pattern across the Korean-influenced category we survey in our overview of how K-beauty is reshaping U.S. aesthetic medicine.
Unapproved is not the same as off-label
The two words are not interchangeable, and the difference changes your legal position. Off-label describes an approved product used outside the indication on its label: approval exists, and the physician exercises judgment supported by an FDA-reviewed safety and manufacturing record. Unapproved means no U.S. approval exists at all — no reviewed label, no established manufacturing standard, no agency finding of safety or effectiveness for anything.
Exosome products are in the second category, so there is nothing for an exosome treatment to be off-label about. If a consent form, web page or staff script in your practice calls it off-label, that language is wrong. The same applies to injectable PDRN and the polynucleotide products patients name from Korean clinics, which is why our explainer on what polynucleotides are and where they stand in the U.S. leads with posture before protocol.
How FDA classifies exosome products
FDA’s position is stated directly in the 2019 notification: “exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products under the Public Health Service Act and the Federal Food Drug and Cosmetic Act and are subject to premarket review and approval requirements.”
Two documents stand between an exosome product and lawful use: an IND to study it in humans, and a BLA to market it. Neither exists for the products circulating in aesthetics, and FDA’s letters say so in those terms — unapproved new drugs in violation of section 505(a) of the FD&C Act, unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act, with “no IND in effect.”
Why the 361 HCT/P exception does not apply
Some human cell and tissue products do reach the market without premarket approval, as 361 HCT/Ps. The criteria in 21 CFR 1271.10(a) are cumulative: the product must be minimally manipulated, intended for homologous use only, manufactured without “the combination of the cells or tissues with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent,” and either free of systemic effect and independent of living-cell metabolic activity, or autologous, used in a close relative, or for reproductive use.
Set that against an exosome product: vesicles isolated from culture, concentrated, often lyophilized, frequently combined with other components, and sold for a purpose unrelated to the source tissue’s function. In candor, FDA has published no §1271.10 analysis for exosomes; what we have is the pattern of its letters, which have never placed an exosome product in the 361 category. In its December 30, 2024 letter to Evolutionary Biologics Inc., FDA applied tissue-product analysis to the firm’s cord- and placenta-derived material while treating the exosome product as an unapproved new drug and unlicensed biologic. The formulation for your own documents is therefore short: unapproved drugs and unlicensed biologics, not tissue grafts and not off-label medicine.
The December 2019 safety notification, and what came after
FDA did not issue that notification in the abstract. It acted after “multiple recent reports of serious adverse events experienced by patients in Nebraska who were treated with unapproved products marketed as containing exosomes,” and stated that certain clinics “deceive patients with unsubstantiated claims.” Four later letters, read in FDA’s own posted text:
- Vitacell Biologics, LLC — untitled letter, January 16, 2024, covering Cytocell Pro, an exosome product, which FDA found are drugs under section 201(g)(1) of the FD&C Act and “also biological products under section 351(i) of the Public Health Service Act.”
- Evolutionary Biologics Inc. — warning letter, December 30, 2024, on the exosome product EXO RNA™, which FDA called “unapproved new drugs” and “unlicensed biological products.”
- Supreme Rejuvenation, LLC — warning letter, May 5, 2025, covering cord-derived exosome products and gels: “no IND in effect for your product. Nor is there a valid biologics license.”
- New Life Medical Services, LLC — warning letter, September 24, 2025, covering the exosome products Rexo and Rexo Charge, citing the 2019 notification.
This posture is current, not historical, and the letters go to manufacturers and distributors — which does not insulate the clinic that buys and injects. Your supply chain is the one FDA is writing to.
Does FDA’s 2025–2026 flexibility change anything?
Agency leadership described a “plausible mechanism pathway” in late 2025 for ultra-rare cell and gene therapies, and FDA announced manufacturing flexibilities for those therapies in January 2026. Neither reaches aesthetic exosome products, and no exosome-specific loosening was located, so treat any pitch built on “approval is coming” as unsupported.
“For research use only” is not a workaround
Much of the exosome material sold into aesthetic practices arrives labeled for research use only, or topical use only. That label is the manufacturer stating in writing the only use it stands behind — and it is the document a plaintiff’s expert will hand a jury. Injecting such a product puts you outside the manufacturer’s instructions and outside any FDA review.
Published harm exists. A 2025 case report in the Journal of Cosmetic Dermatology describes a 38-year-old man who received intradermal injection of a lyophilized product marketed as containing human cord-blood conditioned media, for acne scars. By day three he had ulcerated papules and dusky purple discoloration on both cheeks; the lesions resolved by week two and left severe atrophic scarring with hyperpigmentation, only modestly improved by laser. The manufacturer’s instructions specified topical use only, and the author notes that no exosome product is currently approved for dermal injection. One case is not an incidence rate, but it is a documented, foreseeable mechanism of permanent injury from a common practice pattern.
Topical versus injected: where a cosmetic becomes a drug
The line between a cosmetic and a drug is not drawn by route of administration. It is drawn by intended use, which FDA establishes from the claims in labeling, advertising and promotional material, from consumer perception and from known therapeutic ingredients. Cosmetics are articles “intended to be rubbed, poured, sprinkled, or sprayed on … for cleansing, beautifying, promoting attractiveness, or altering the appearance” under FD&C Act 201(i); drugs include articles “intended to affect the structure or any function of the body” under 201(g)(1). So a serum sold to beautify may sit within cosmetics, while the identical serum sold to regenerate tissue, heal or remodel collagen is being marketed as an unapproved drug — and your website and your intake conversation are evidence of intended use.
One limit: no FDA document addressing human-derived exosomes as a cosmetic ingredient could be located, so the intended-use test is the only framework that applies. Most retail topicals labeled “exosome” are plant or other non-human vesicles, conditioned media or lysates, and it is the human-derived route regulators restrict. Our reference page on exosomes in regenerative aesthetics and our article on exosome facial treatments for skin rejuvenation are the starting points if you retail these products.
What Korea actually allows
Patients cite Seoul, so note that Korea is stricter than the mythology suggests. It prohibits human cells, tissues and their culture media in cosmetics unless the material meets Appendix 3 of its Regulation on Safety Standards for Cosmetics (Notice No. 2023-73, November 30, 2023). And per a January 21, 2025 MFDS announcement revising the cosmetic labeling and advertising guidelines, prohibited expressions now include human-derived-ingredient claims, naming “exosomes” and “liposomes” specifically. An effective date for that revision could not be confirmed.
Ready to put this into practice?
Explore Empire's hands-on, CME-accredited Functional & Regenerative Medicine courses — live patients, expert faculty, and ongoing mentorship.
So Korea has not approved human-derived exosome cosmetics and has restricted the marketing word itself. The patient who believes Seoul has an approved product America is withholding is mistaken.
State law does not move the federal line
Florida’s CS/CS/SB 1768 is the state law providers ask about most. Effective July 1, 2025, it created Fla. Stat. §§458.3245 and 459.0127, permitting physicians to perform and advertise stem cell therapies FDA has not approved, subject to sourcing, consent and advertising conditions, including the notice “This physician performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration.”
Three points matter for anyone reading that as an exosome opening. Its definition of stem cell therapy does not mention exosomes, extracellular vesicles, secretome or derivatives. Its permitted uses are limited to orthopedics, wound care and pain management, so cosmetic and anti-aging indications are not covered. And a state statute cannot authorize what federal law prohibits; FDA jurisdiction is unchanged. Florida did not legalize exosome therapy.
Where your exposure actually sits
Four channels, and the FDA letter providers picture is the least likely.
- Federal. FDA’s letters go to manufacturers and distributors, but marketing an unapproved drug is the conduct at issue, and clinic-facing claims are marketing.
- State licensing boards. Boards act on misleading advertising, on consent that omits material facts, and on scope — a faster and likelier route than federal action.
- Malpractice. Standard of care is where the research-use-only label and the published necrosis case become expert-report material. Some carriers also limit coverage for unapproved products.
- Informed consent. State plainly that no exosome product is FDA-approved for any indication, that it is unapproved rather than off-label, the route used versus the labeled route, what the evidence supports, and the alternatives — including autologous options such as PRP and PRF.
Answering the patient who read about a Seoul clinic
The request usually arrives as a product name rather than a goal, and the goal is achievable with something you can lawfully offer.
Be accurate about the evidence in both directions. A 12-week randomized, split-face study of 28 patients found global aesthetic improvement significantly higher on the side treated with an exosome-containing solution plus microneedling than on the saline side (p = 0.005), and a 2026 meta-analysis of 39 human studies reported an average 20.2% reduction in facial wrinkles (95% CI 15.3–25.2). Those same authors note that heterogeneity and nonstandardized protocols limit generalizability, and a second 2026 review of 21 studies found most had low-to-moderate rigor with inconsistent product characterization. A positive trial of one proprietary solution says little about another vendor’s vial.
So name the regulatory fact early and without drama: there is no FDA-approved exosome product here, so it is not something you can responsibly inject. Then pivot to what the patient wants — skin quality, texture, early collagen support — and offer modalities with an approval or an autologous pathway behind them. Our comparison of exosomes, PDRN and PRP lays those options side by side, patients who want the stem-cell framing are served by our piece on exosomes versus stem cells, and the wider pattern of product-name requests sits in our article on how Korean aesthetic philosophy is reshaping patient expectations. What not to do is promise that approval is imminent.
Frequently asked questions
Are exosomes FDA-approved?
No. FDA states that “there are currently no FDA-approved exosome products,” language that has stood since its December 6, 2019 public safety notification and is repeated on the agency’s regenerative medicine consumer alert. That covers every indication, and searches of FDA’s drug-label and device databases for “exosome” return no match.
Are exosomes safe?
Safety cannot be established for a class with no approved manufacturing standard and no characterization requirement; one vendor’s vial tells you little about another’s. Small cosmetic studies reported no serious adverse events, but FDA acted in 2019 on serious adverse events in Nebraska patients, and a 2025 case report documents necrosis and permanent scarring.
Can I legally offer exosome treatments?
These products are unapproved new drugs and unlicensed biologics under federal law, with no IND or BLA in place, so no federal pathway authorizes offering them in aesthetic practice. Separate exposure runs through state board advertising and consent rules and through malpractice standard of care. Put the question to your counsel and carrier in writing before you buy product.
What does “research use only” mean?
It means the manufacturer is selling the material for laboratory research, not representing it as suitable for human treatment. It confers no permission to inject and is not equivalent to an approved label.
Are topical exosome products regulated differently?
Route alone does not decide it; intended use does. A topical sold to beautify or alter appearance can sit within cosmetics, while the same product sold to regenerate, heal or remodel collagen is being marketed as an unapproved drug.
Do exosomes work?
The signal in human skin studies is positive but modest, and the quality of the evidence is the real story: small, mostly short, often unblinded trials on proprietary products. “Promising and unstandardized” is the accurate summary, and it is not the same claim as “effective.”
Where to learn this properly
Empire teaches the regenerative category with the regulatory posture attached, because in practice the two are not separable. The Facial Contouring Injectables: Sculptra®, Radiesse®, Exosomes & PDRN Certification Workshop is a hands-on course covering preparation, dilution and injection technique for Sculptra (poly-L-lactic acid) and Radiesse (calcium hydroxylapatite), integration of exosome therapy and PDRN into facial and skin rejuvenation protocols, layering with PDO threads, PRP and PRF, cannula technique, and complication management. It is open to MD/DO, DMD/DDS, NP, PA and RN attendees, and it is a non-CME workshop.
For the regulatory side in depth, the Peptide Therapy Certification curriculum addresses it directly: Module 9 covers exosome products and their current U.S. regulatory posture alongside PDRN and polynucleotide skin protocols, and Module 5.5 covers PRP, exosomes and combination regenerative procedures. The certification is a founding-cohort program still in development. For the procedure itself, see our piece on what professionals should know about exosome injection.
